EcoDrugPlus

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSSLDG00000014161
Gene Symbol: SIGMAR1
3 Cross references
203 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1-Like

Ensembl ID : ENSSLDG00000005726
Gene Symbol: LOC111657337
3 Cross references
203 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSSLDG00000019885
Gene Symbol: SIRT1
3 Cross references
156 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSSLDG00000025077
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 2 Subunit Alpha-Like

Ensembl ID : ENSSLDG00000003505
Gene Symbol: LOC111666512
3 Cross references
71 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSSLDG00000002051
Gene Symbol: LOC111667721
2 Cross references
215 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSSLDG00000011743
Gene Symbol: SCN4A
4 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSSLDG00000005220
Gene Symbol: SCN8A
4 Cross references
215 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSSLDG00000011897
Gene Symbol: LOC111672209
3 Cross references
205 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSSLDG00000006733
Gene Symbol: LOC111665251
2 Cross references
215 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSSLDG00000006609
Gene Symbol: LOC111668406
3 Cross references
205 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSSLDG00000017566
Gene Symbol: LOC111653962
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).